Ed

Just as an example of how crazy the prices are, there's this diabetes medication I was looking at called Jardiance. One month's supply costs $611 in America. In Japan, it costs $35. It's not as if everyone in Japan is poor in the prices. I mean, that's just an unbelievable... And again, the markets are telling us the true story here.

I mean, Trump comes out and he says over the weekend that he wants to pursue this most favored nation policy, which basically means that drugs must be priced at their cheapest levels for the US. If that drug costs $35 in Japan, it should cost $35 in America. And it's such a shame because I was actually very excited to see that.

I mean, Trump comes out and he says over the weekend that he wants to pursue this most favored nation policy, which basically means that drugs must be priced at their cheapest levels for the US. If that drug costs $35 in Japan, it should cost $35 in America. And it's such a shame because I was actually very excited to see that.

I mean, Trump comes out and he says over the weekend that he wants to pursue this most favored nation policy, which basically means that drugs must be priced at their cheapest levels for the US. If that drug costs $35 in Japan, it should cost $35 in America. And it's such a shame because I was actually very excited to see that.

I mean, he's going after the right issues, which is we need to do something to lower the cost of drugs and the price of drugs in America and pharmaceuticals. And the fact that the market was reacting and getting worried about it and these pharma stocks were hurting as a result of those comments, to me, was a great sign. But then, of course...

I mean, he's going after the right issues, which is we need to do something to lower the cost of drugs and the price of drugs in America and pharmaceuticals. And the fact that the market was reacting and getting worried about it and these pharma stocks were hurting as a result of those comments, to me, was a great sign. But then, of course...

I mean, he's going after the right issues, which is we need to do something to lower the cost of drugs and the price of drugs in America and pharmaceuticals. And the fact that the market was reacting and getting worried about it and these pharma stocks were hurting as a result of those comments, to me, was a great sign. But then, of course...

the whole thing came undone when suddenly he signs the executive order and you learn actually there's nothing to do with this most favored nation policy all he's doing is saying hey guys please reduce the cost of drugs and then all the pharma stocks rip back up because basically wall street's reaction is great that means prices are not going to come down if you simply ask

the whole thing came undone when suddenly he signs the executive order and you learn actually there's nothing to do with this most favored nation policy all he's doing is saying hey guys please reduce the cost of drugs and then all the pharma stocks rip back up because basically wall street's reaction is great that means prices are not going to come down if you simply ask

the whole thing came undone when suddenly he signs the executive order and you learn actually there's nothing to do with this most favored nation policy all he's doing is saying hey guys please reduce the cost of drugs and then all the pharma stocks rip back up because basically wall street's reaction is great that means prices are not going to come down if you simply ask

a company to reduce their prices, they won't reduce their prices. This is market dynamics. They're only going to do it if they have to. And the only way you can do that is by pursuing a legitimate legal framework that forces them to bring down their prices. And that's not what's happening. So it was a shame for me because I was about to be very... of Trump and this move and what he's addressing.

a company to reduce their prices, they won't reduce their prices. This is market dynamics. They're only going to do it if they have to. And the only way you can do that is by pursuing a legitimate legal framework that forces them to bring down their prices. And that's not what's happening. So it was a shame for me because I was about to be very... of Trump and this move and what he's addressing.

a company to reduce their prices, they won't reduce their prices. This is market dynamics. They're only going to do it if they have to. And the only way you can do that is by pursuing a legitimate legal framework that forces them to bring down their prices. And that's not what's happening. So it was a shame for me because I was about to be very... of Trump and this move and what he's addressing.

And I was thinking it would be one of the first things where I'm like, yeah, he's got this right. But once again, he just shows that he lacks the competence to actually follow through with these things. And so it's going to continue business as usual.

And I was thinking it would be one of the first things where I'm like, yeah, he's got this right. But once again, he just shows that he lacks the competence to actually follow through with these things. And so it's going to continue business as usual.

And I was thinking it would be one of the first things where I'm like, yeah, he's got this right. But once again, he just shows that he lacks the competence to actually follow through with these things. And so it's going to continue business as usual.

Let's talk about perplexity, which is raising a round that would value the company at $14 billion. That's up from its $9 billion valuation from just a few months ago. this is the AI company competing with OpenAI. The deal isn't finalized, but I think we can assume it's as good as finalized. I mean, these leaked journal reports are usually pretty spot on.

Let's talk about perplexity, which is raising a round that would value the company at $14 billion. That's up from its $9 billion valuation from just a few months ago. this is the AI company competing with OpenAI. The deal isn't finalized, but I think we can assume it's as good as finalized. I mean, these leaked journal reports are usually pretty spot on.

Let's talk about perplexity, which is raising a round that would value the company at $14 billion. That's up from its $9 billion valuation from just a few months ago. this is the AI company competing with OpenAI. The deal isn't finalized, but I think we can assume it's as good as finalized. I mean, these leaked journal reports are usually pretty spot on.

So assuming it is, that would make Perplexity the fourth most valuable AI startup. Ahead of Perplexity, we've got OpenAI at $300 billion. We've got XAI at $80 billion, though, as I've discussed, that number is kind of bullshit, but whatever, we'll ignore that. And we've got Anthropic at $62 billion. Perplexity is number four.